Sanofi has set up a warranty program to pay back some medical institutions who administered Cablivi, an antibody-based treatment for a rare clotting disease. The company will reimburse healthcare institutions the cost of 6 doses for patients who do not see improvements and 12 doses for patients whose conditions worsen during treatment
According to Nicole DeFeudis, “Other companies are joining the wave. BioMarin has previously said it plans to offer an outcomes-based warranty for Roctavian, which would be “ready to implement with payers at launch” if the drug wins an approval in hemophilia A. And back in October 2021, Takeda inked a deal with insurance provider Point32Health that provides certain lung cancer patients access to Alunbrig through an ‘outcomes-based structure.’”
To read more, click here.
(Source: Endpoints News, January 20th, 2023)
